Back to Lung Cancer
NCT00363415
NCT00363415
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with small cell lung cancer (SCLC) that has spread widely in the body (called "extensive stage")
- You are able to take care of yourself day-to-day, even if you are unable to do regular work activities
- You have not yet received any cancer treatments for your small cell lung cancer
Who may not be able to join:
- You have previously taken part in a clinical study that involved a drug called pemetrexed
- You have received a drug in the last 30 days that has not yet been officially approved for use by health regulators for any medical condition
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 3
Sponsor
Eli Lilly and Company
Registry
clinicaltrials_gov
Start date
1 August 2006
Est. completion
1 June 2008
Where this trial is recruiting
🇦🇷 Argentina
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇧🇷 Brazil
🇨🇳 China
🇫🇷 France
🇩🇪 Germany
🇬🇷 Greece
🇭🇺 Hungary
🇮🇳 India
🇮🇹 Italy
🇳🇱 Netherlands
🇳🇿 New Zealand
🇵🇱 Poland
🇵🇹 Portugal
Puerto Rico
🇷🇴 Romania
🇷🇺 Russia
🇿🇦 South Africa
🇰🇷 South Korea
🇪🇸 Spain
🇹🇼 Taiwan
Turkey (Türkiye)
🇬🇧 United Kingdom
🇺🇸 United States
15 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Overall Survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.